Skip to content
PaperFren

public-health

Is Iran’s diabetes cascade improving over time?

Khodakarami R, Abdi Z, Ahmadnezhad E, et al. · BMC public health · 2022

Open access · cc by · source: Europe PMC

From 2004–2016 prevalence rose 8.4%→13.2% and awareness 53.5%→82.2%, but treatment (~36–46%) and control (~15–21%) stayed suboptimal.

Key findings

Prevalence and awareness climbed; treatment peaked then dipped; control remained low. Female sex, age>40, urban residence, mid wealth, and insurance associated with prevalence.

Methodology

Analyzed four STEPS NCD surveys with descriptive stats and logistic regression for sociodemographic correlates of awareness/treatment/control.

Limitations

Does not evaluate a specific intervention trial; age/sex unadjusted prevalence trends as reported.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • SupportsDiabetes care cascadeconcept

    National STEPS data can show rising awareness while control stays low.

    Iranian STEPS analyses found diabetes prevalence and awareness climbing, treatment peaking then dipping, and glycemic control remaining low—illustrating cascade leakage after detection.

    Evidence for the claim as stated.

  • QualifiesDiabetes care cascadeconcept

    Many countries run T2DM detection/adherence programs, but authors still judge them insufficient for rising burden.

    A review of ongoing T2DM care activities highlights detection, monitoring, and adherence efforts amid obesity/urbanization drivers and HIV/TB co-morbidity, while arguing current efforts under-match need.

    Scope note — one-country cascade metrics ≠ proof any listed program closed control gaps

    Limits the claim's scope: a different population, assay, or outcome.

  • QualifiesDiabetes care cascadeconcept

    Smartphone self-management tools are one narrow cascade lever, not a system fix.

    A smartphone diabetes self-management application study for adults with type 1 diabetes tests digital support for day-to-day management rather than national awareness/treatment/control rates.

    Scope note — app trial ≠ population effective coverage

    Limits the claim's scope: a different population, assay, or outcome.

  • SupportsDiabetes care cascadeconcept

    Awareness up, control still low in national survey vs Many programs exist but judged insufficient vs App-level self-management support in T1D

    Evidence for the claim as stated.

Open questions

Tensions this paper is part of

From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.

Related papers in this topic

Same topic cluster — not a recommendation engine.